OrbiMed’s Alpine Immune Sciences Inc ALPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-2,680,496
Closed -$106M 125
2024
Q1
$106M Buy
2,680,496
+145,251
+6% +$4.29M 1.95% 12
2023
Q4
$48.3M Sell
2,535,245
-1,546,347
-38% -$21.5M 0.97% 38
2023
Q3
$46.7M Hold
4,081,592
0.99% 38
2023
Q2
$42M Hold
4,081,592
0.76% 47
2023
Q1
$31.5M Hold
4,081,592
0.62% 54
2022
Q4
$30M Hold
4,081,592
0.57% 58
2022
Q3
$29.4K Hold
4,081,592
0.55% 60
2022
Q2
$34.7K Hold
4,081,592
0.63% 49
2022
Q1
$36.6M Hold
4,081,592
0.59% 48
2021
Q4
$56.5M Hold
4,081,592
0.73% 45
2021
Q3
$43.6M Buy
4,081,592
+1,010,637
+33% +$9.31M 0.48% 59
2021
Q2
$27.6M Hold
3,070,955
0.28% 86
2021
Q1
$32.6M Hold
3,070,955
0.3% 78
2020
Q4
$38.7M Sell
3,070,955
-600,000
-16% -$5.89M 0.34% 71
2020
Q3
$32.3M Hold
3,670,955
0.41% 66
2020
Q2
$35.6M Hold
3,670,955
0.5% 58
2020
Q1
$10.6M Hold
3,670,955
0.18% 84
2019
Q4
$14.1M Hold
3,670,955
0.2% 73
2019
Q3
$14.5M Hold
3,670,955
0.28% 73
2019
Q2
$15.5M Hold
3,670,955
0.24% 79
2019
Q1
$25.2M Buy
3,670,955
+372,439
+11% +$2.32M 0.39% 63
2018
Q4
$12.1M Hold
3,298,516
0.22% 81
2018
Q3
$20.9M Hold
3,298,516
0.25% 87
2018
Q2
$25M Hold
3,298,516
0.3% 75
2018
Q1
$26.4M Hold
3,298,516
0.33% 71
2017
Q4
$36.9M Hold
3,298,516
0.47% 62
2017
Q3
$38.3M Buy
+3,298,516
New +$30.8M 0.37% 73
2016
Q4
Sell
-14,750
Closed -$480K 142
2016
Q3
$480K Buy
+14,750
New +$359K 0.01% 138

OrbiMed's ALPN Position: Q2 2024 in Review

OrbiMed sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 2,680,496 shares — an estimated $106M sold.

OrbiMed first reported a position in ALPN in Q3 2016 and held it in 28 quarters. The position peaked at $106M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

  • OrbiMed reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
  • OrbiMed sold 2,680,496 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $106M.
  • OrbiMed first reported a position in Alpine Immune Sciences Inc in Q3 2016 and held it in 28 quarters.
  • OrbiMed's Alpine Immune Sciences Inc position peaked at $106M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on OrbiMed's 13F filing for Q2 2024, filed 14 Aug 2024.